Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Apricitabine Development Should Not Be Halted, Say HIV/AIDS Advocates in Open Letter

June 21, 2010

[Following is the text of an open letter sent on June 17 by the AIDS Treatment Activists Coalition and European AIDS Treatment Group. The letter was addressed to Susan Cox, the former senior vice president of drug development at Avexa; copies were sent to Nathan Drona, Avexa's chairman, and Stephen Kerr, the company's board secretary.]

We, the undersigned, are asking the decision makers at Avexa to reconsider the decision to stop the development of apricitabine, a nucleoside analog that has shown good efficacy in patients with the most common nucleoside mutation, M184V. Physicians and a growing number of patients with limited treatment options have been counting on the approval of this drug to enable the construction of effective regimens. Apricitabine can mean the tipping point between success and failure of a salvage regimen -- between life and death.

View Full Article


  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
More on HIV Medications
More on NRTIs in Development

Reader Comments:

Comment by: Worthind (Sydney) Tue., Jun. 22, 2010 at 7:09 am EDT
everyone agrees about the potential of ATC
it will help people and save lives

when will the FDA/EMEA clarify a clear path to market for these types of drugs

Avexa will get the drug to market with a pharma partner once the path is clear
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement